文献速递瓣膜外科

三种主动脉生物瓣膜5年血流动力学表现:一项随机临床试验

5-Year haemodynamic performance of three aortic bioprostheses. A randomized clinical trial.
PubMed 文献 · Eur J Cardiothorac Surg · 2023-01-01

BEST-VALVE单中心随机临床试验纳入154例患者,比较Carpentier Perimount Magna Ease、Crown PRT和Trifecta三种主动脉生物瓣膜的5年血流动力学与临床结局。CP Magna Ease组平均主动脉压差最低,血流动力学表现最佳;Trifecta组6年随访时严重结构性瓣膜退化累积发生率为9.5%。三组全因死亡生存率和复合事件生存率无显著差异。

要点

  • CP Magna Ease组5年平均主动脉压差12.3 mmHg,低于Crown PRT组15 mmHg和Trifecta组14.7 mmHg,差异均有统计学意义(P < 0.001)
  • Trifecta组6年随访严重结构性瓣膜退化累积发生率为9.5%
  • 三组1年、3年、5年全因死亡生存率分别为91.5%、83.5%、74.8%(log rank P = 0.440),复合事件生存率分别为92.8%、74.6%、59%(log rank P = 0.299)

核心结论

  • 三种主动脉生物瓣膜间存在显著差异,CP Magna Ease在5年随访时血流动力学表现最佳。

研究设计与样本

  • BEST-VALVE为单中心随机临床试验,比较上述三种生物瓣膜的血流动力学与临床结局,本稿报告5年结果。
  • 共纳入154例患者,CP Magna Ease组48例(31.2%),Crown PRT组51例(32.1%),Trifecta组55例(35.7%)。

主要发现

  • CP Magna Ease组平均主动脉压差12.3 mmHg(IQR 7.8-17.5)vs Crown PRT组15 mmHg(IQR 10.8-31.9),P < 0.001。
  • CP Magna Ease组平均主动脉压差12.3 mmHg(IQR 7.8-17.5)vs Trifecta组14.7 mmHg(IQR 8.2-55),P < 0.001。
  • Trifecta组6年随访严重结构性瓣膜退化累积发生率为9.5%。
  • 1年、3年、5年全因死亡生存率分别为91.5%、83.5%、74.8%(log rank P = 0.440)。
  • 1年、3年、5年复合事件生存率分别为92.8%、74.6%、59%(log rank P = 0.299)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Carpentier Perimount (CP) Magna Ease, the Crown Phospholipid Reduction Treatment (PRT) and the Trifecta bovine pericardial valves have been widely used worldwide. The primary end point of this study was to compare the haemodynamic performance quantified by in vivo echocardiograms of these 3 aortic prostheses. METHODS: The "BEST-VALVE" (comparison of 3 contemporary cardiac bioprostheses: mid-term valve haemodynamic performance) was a single-centre randomized clinical trial to compare the haemodynamic and clinical outcomes of the aforementioned bioprostheses. The 5-year results are assessed in this manuscript. RESULTS: A total of 154 patients were included. The CP Magna Ease (n = 48, 31.2%), Crown PRT (n = 51, 32.1%) and Trifecta (n = 55, 35.7%) valves were compared. Significant differences were observed among the 3 bioprostheses 5 years after the procedure. The following haemodynamic differences were found between the CP Magna Ease and the Crown PRT bioprostheses [mean aortic gradient: 12.3 mmHg (interquartile range {IQR} 7.8-17.5) for the CP Magna Ease vs 15 mmHg (IQR 10.8-31.9) for the Crown PRT, P < 0.001] and between the CP Magna Ease and the Trifecta prostheses [mean aortic gradient: 12.3 mmHg (IQR 7.8-17.5) for the CP Magna Ease vs 14.7 mmHg (IQR 8.2-55) for the Trifecta, P < 0.001], with a better haemodynamic performance of the CP Magna Ease. The cumulative incidence of severe structural valve degeneration was 9.5% in the Trifecta group at 6 years of follow-up. The 1-, 3- and 5-year survival from all-cause mortality was 91.5%, 83.5% and 74.8%, respectively (log rank P = 0.440). Survival from the composite event at the 1-, 3- and 5-year follow-up was 92.8%, 74.6% and 59%, respectively (log rank P = 0.299). CONCLUSIONS: We detected significant differences between the 3 bioprostheses; the CP Magna Ease had the best haemodynamic performance at the 5-year follow-up.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Montero Cruces L, Carnero Alcázar M, Pérez Camargo D, et al. 5-Year haemodynamic performance of three aortic bioprostheses. A randomized clinical trial. Eur J Cardiothorac Surg. 2023. PMID: 37471587. doi:10.1093/ejcts/ezad261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。